Long-Term Effects of Iron Chelating Agents on Ocular Function in Patients with Thalassemia Major

References

• Galanello R, Origa R. Beta-thalassemia. Orphanet J Rare Dis. 2010;10.
   Google Scholar
• Martin A, Thompson AA. Thalassemias. Pediatr Clin North Am. 2013;60(6):1383–1391. doi:10.1016/j.pcl.2013.08.008
   PubMed Web of Science ®Google Scholar
• Joly P, Pondarre C, Badens C. [Beta-thalassemias: molecular, epidemiological, diagnostical and clinical aspects]. Ann Biol Clin (Paris). 2014;72(6):639–668. Indonesian. doi:10.1684/abc.2014.1015.
   PubMed Web of Science ®Google Scholar
• Rachmilewitz EA, Giardina PJ. How I treat thalassemia. Blood. 2011;118(13):3479–3488. doi:10.1182/blood-2010-08-300335
   PubMed Web of Science ®Google Scholar
• Dubey AP, Parakh A, Dublish S. Current trends in the management of beta thalassemia. Indian J Pediatr. 2008;75(7):739–743. doi:10.1007/s12098-008-0140-4
   PubMed Web of Science ®Google Scholar
• Angelucci E, Barosi G, Camaschella C, et al. Italian Society of Hematology practice guidelines for the management of iron overload in thalassemia major and related disorders. Haematologica. 2008;93(5):741–752. doi:10.3324/haematol.12413
   PubMed Web of Science ®Google Scholar
• Langhi DJ, Ubiali EMA, Marques JFCJ, et al. Guidelines on Beta-thalassemia major - regular blood transfusion therapy: associacao brasileira de hematologia, hemoterapia e terapia celular: project guidelines: associacao Medica Brasileira - 2016. Rev Bras Hematol Hemoter. 2016;38(4):341–345. doi:10.1016/j.bjhh.2016.09.003
   PubMedGoogle Scholar
• Prati D. Benefits and complications of regular blood transfusion in patients with beta-thalassaemia major. Vox Sang. 2000;79(3):129–137. doi:10.1046/j.1423-0410.2000.7930129.x
   PubMed Web of Science ®Google Scholar
• Maggio A, Filosa A, Vitrano A, et al. Iron chelation therapy in thalassemia major: a systematic review with meta-analyses of 1520 patients included on randomized clinical trials. Blood Cells Mol Dis. 2011;47(3):166–175. doi:10.1016/j.bcmd.2011.07.002
   PubMed Web of Science ®Google Scholar
• Kontoghiorghe CN, Kontoghiorghes GJ. Efficacy and safety of iron-chelation therapy with deferoxamine, deferiprone, and deferasirox for the treatment of iron-loaded patients with nontransfusion-dependent thalassemia syndromes. Drug Des Devel Ther. 2016;10:465–481. doi:10.2147/DDDT.S79458
   PubMed Web of Science ®Google Scholar
• Xia S, Zhang W, Huang L, Jiang H. Comparative efficacy and safety of deferoxamine, deferiprone and deferasirox on severe thalassemia: a meta-analysis of 16 randomized controlled trials. PLoS One. 2013;8(12):e82662. doi:10.1371/journal.pone.0082662
   PubMed Web of Science ®Google Scholar
• Hassan MAM, Tolba OA. Iron chelation monotherapy in transfusion-dependent beta-thalassemia major patients: a comparative study of deferasirox and deferoxamine. Electron Physician. 2016;8(5):2425–2431. doi:10.19082/2425
   PubMedGoogle Scholar
• Borgna-Pignatti C, Marsella M. Iron Chelation in Thalassemia Major. Clin Ther. 2015;37(12):28662877. doi:10.1016/j.clinthera.2015.10.001
   Web of Science ®Google Scholar
• Saliba AN, Harb AR, Taher AT. Iron chelation therapy in transfusion-dependent thalassemia patients: current strategies and future directions. J Blood Med. 2015;6:197–209. doi:10.2147/JBM.S72463
   PubMed Web of Science ®Google Scholar
• Porter JB. Optimizing iron chelation strategies in beta-thalassaemia major. Blood Rev. 2009;23(Suppl 1):S3–7. doi:10.1016/S0268-960X(09)70003-7
   PubMed Web of Science ®Google Scholar
• Cohen AR, Galanello R, Piga A, Dipalma A, Vullo C, Tricta F. Safety profile of the oral iron chelator deferiprone: a multicentre study. Br J Haematol. 2000;108(2):305–312. doi:10.1046/j.1365-2141.2000.01866.x
   PubMed Web of Science ®Google Scholar
• Al-Khabori M, Bhandari S, Al-Huneini M, Al-Farsi K, Panjwani V, Daar S. Side effects of Deferasirox Iron Chelation in patients with beta thalassemia major or intermedia. Oman Med J. 2013;28(2):121124. doi:10.5001/omj.2013.31
   Google Scholar
• Mehdizadeh M, Nowroozzadeh MH. Posterior subcapsular opacity in two patients with thalassaemia major following deferiprone consumption. Clin Exp Optom. 2009;92(4):392–394. doi:10.1111/j.14440938.2009.00385.x
   Web of Science ®Google Scholar
• Parakh N, Sharma R, Prakash O, et al. Neurological complications and cataract in a child with thalassemia major treated with deferiprone. J Pediatr Hematol Oncol. 2015;37(7):e433–4. doi:10.1097/MPH.0000000000000391
   Web of Science ®Google Scholar
• Davies SC, Marcus RE, Hungerford JL, Miller MH, Arden GB, Huehns ER. Ocular toxicity of high-dose intravenous desferrioxamine. Lancet. 1983;2(8343):181–184. doi:10.1016/S0140-6736(83)90170-8
   PubMed Web of Science ®Google Scholar
• Bansal V, Elgarbly I, Ghanchi FD, Atkinson PL. Bull’s eye maculopathy with deferoxamine. Eur J Haematol. 2003;70(6):420–421. doi:10.1034/j.1600-0609.2003.00073.x
   Web of Science ®Google Scholar
• Gelman R, Kiss S, Tsang SH. Multimodal imaging in a case of deferoxamine-induced maculopathy. Retin Cases Brief Rep. 2014;8(4):306–309. doi:10.1097/ICB.0000000000000059
   PubMedGoogle Scholar
• Genead MA, Fishman GA, Anastasakis A, Lindeman M. Macular vitelliform lesion in desferrioxaminerelated retinopathy. Doc Ophthalmol. 2010;121(2):161–166. doi:10.1007/s10633-010-9236-z
   Web of Science ®Google Scholar
• Lai TYY, Lee GKY, Chan W-M, Lam DSC. Rapid development of severe toxic retinopathy associated with continuous intravenous deferoxamine infusion. Br J Ophthalmol. 2006;90(2):243–244. doi:10.1136/bjo.2005.080119
   PubMed Web of Science ®Google Scholar
• Lu M, Hansen RM, Cunningham MJ, Eklund SE, Fulton AB. Effects of desferoxamine on retinal and visual function. Arch Ophthalmol. 2007;125(11):1581–1582. doi:10.1001/archopht.125.11.1581
   Google Scholar
• Simon S, Athanasiov PA, Jain R, Raymond G, Gilhotra JS. Desferrioxamine-related ocular toxicity: a case report. Indian J Ophthalmol. 2012;60(4):315–317. doi:10.4103/0301-4738.98714
   PubMed Web of Science ®Google Scholar
• Wu C-H, Yang C-P, Lai -C-C, Wu W-C, Chen Y-H. Deferoxamine retinopathy: spectral domain-optical coherence tomography findings. BMC Ophthalmol. 2014;14(1):88. doi:10.1186/1471-2415-14-88
   Web of Science ®Google Scholar
• Vahdani K, Makrygiannis G, Kaneshyogan H, Sian IS, Giasin O. Bilateral central serous retinopathy in a patient with paroxysmal nocturnal hemoglobinuria treated with deferoxamine. Eur J Ophthalmol. 2016;26(6):e152–e154. doi:10.5301/ejo.5000840
   PubMed Web of Science ®Google Scholar
• De Virgiliis S, Congia M, Turco MP, et al. Depletion of trace elements and acute ocular toxicity induced by desferrioxamine in patients with thalassaemia. Arch Dis Child. 1988;63(3):250–255. doi:10.1136/adc.63.3.250
   PubMed Web of Science ®Google Scholar
• El-Shazly AAE-F, Elkitkat RS, Ebeid WM, Deghedy MR. CORRELATION BETWEEN SUBFOVEAL CHOROIDAL THICKNESS AND FOVEAL THICKNESS IN THALASSEMIC PATIENTS. Retina. 2016;36(9):1767–1772. doi:10.1097/IAE.0000000000000970
   Web of Science ®Google Scholar
• Triantafyllou N, Fisfis M, Sideris G, et al. Neurophysiological and neuro-otological study of homozygous beta-thalassemia under long-term desferrioxamine (DFO) treatment. Acta Neurol Scand. 1991;83(5):306–308. doi:10.1111/j.1600-0404.1991.tb04707.x
   Web of Science ®Google Scholar
• Bhoiwala DL, Dunaief JL. Retinal abnormalities in beta-thalassemia major. Surv Ophthalmol. 2016;61(1):33–50. doi:10.1016/j.survophthal.2015.08.005
   Web of Science ®Google Scholar
• Arden GB, Wonke B, Kennedy C, Huehns ER. Ocular changes in patients undergoing long-term desferrioxamine treatment. Br J Ophthalmol. 1984;68(12):873–877. doi:10.1136/bjo.68.12.873
   PubMed Web of Science ®Google Scholar
• Chen S-H, Liang D-C, Lin H-C, Cheng S-Y, Chen L-J, Liu H-C. Auditory and visual toxicity during deferoxamine therapy in transfusion-dependent patients. J Pediatr Hematol Oncol. 2005;27(12):651653. doi:10.1097/01.mph.0000194019.95096.b6
   Web of Science ®Google Scholar
• Gartaganis SP, Zoumbos N, Koliopoulos JX, Mela EK. Contrast sensitivity function in patients with beta-thalassemia major. Acta Ophthalmol Scand. 2000;78(5):512–515. doi:10.1034/j.1600-0420.2000.078005512.x
   Google Scholar
• Olivieri NF, Buncic JR, Chew E, et al. Visual and auditory neurotoxicity in patients receiving subcutaneous deferoxamine infusions. N Engl J Med. 1986;314(14):869–873. doi:10.1056/NEJM198604033141402
   PubMed Web of Science ®Google Scholar
• Viola F, Barteselli G, Dell’Arti L, et al. Multimodal imaging in deferoxamine retinopathy. Retina. 2014;34(7):1428–1438. doi:10.1097/IAE.0000000000000073
   PubMed Web of Science ®Google Scholar
• Viola F, Barteselli G, Dell’arti L, et al. Abnormal fundus autofluorescence results of patients in longterm treatment with deferoxamine. Ophthalmology. 2012;119(8):1693–1700. doi:10.1016/j.ophtha.2012.01.039
   PubMed Web of Science ®Google Scholar
• Wong V, Li A, Lee AC. Neurophysiologic study of beta-thalassemia patients. J Child Neurol. 1993;8(4):330–335. doi:10.1177/088307389300800407
   PubMed Web of Science ®Google Scholar
• Cohen A, Martin M, Mizanin J, Konkle DF, Schwartz E. Vision and hearing during deferoxamine therapy. J Pediatr. 1990;117(2 Pt 1):326–330. doi:10.1016/S0022-3476(05)80556-6
   PubMed Web of Science ®Google Scholar
• Merchant RH, Punde H, Thacker N, Bhatt D. Ophthalmic Evaluation in Beta-Thalassemia. Indian J Pediatr. 2017;84(7):509–514. doi:10.1007/s12098-017-2339-8
   PubMed Web of Science ®Google Scholar
• Masera N, Rescaldani C, Azzolini M, et al. Development of lens opacities with peculiar characteristics in patients affected by thalassemia major on chelating treatment with deferasirox (ICL670) at the pediatric clinic in Monza, Italy. Haematologica. 2008;93(1):e9–10. doi:10.3324/haematol.11782
   PubMed Web of Science ®Google Scholar
• Ford JM, Rojkjaer L. Comment to: development of lens opacities with peculiar characteristics in patients affected by thalassemia major on chelating treatment with deferasirox. Haematologica. 2008;93(6):e9–10. doi:10.3324/haematol.12944
   Web of Science ®Google Scholar
• Piga A, Longo F, Musallam KM, et al. Assessment and management of iron overload in beta thalassemia major patients during the 21st century: a real-life experience from the Italian WEBTHAL project. Br J Haematol. 2013;161(6):872–883. doi:10.1111/bjh.12340
   Web of Science ®Google Scholar
• Jethani J, Marwah K, Patel S, Shah B. Ocular abnormalities in patients with beta thalassemia on transfusion and chelation therapy: our experience. Indian J Ophthalmol. 2010;58(5):451–452. doi:10.4103/0301-4738.67061
   Web of Science ®Google Scholar
• Incorvaia C, Parmeggiani F, Costagliola C, Perri P, D’Angelo S, Sebastiani A. Quantitative evaluation of the retinal venous tortuosity in chronic anaemic patients affected by beta-thalassaemia major. Eye (Lond). 2003;17(3):324–329. doi:10.1038/sj.eye.6700352
   Web of Science ®Google Scholar
• Sheeladevi S, Lawrenson JG, Fielder AR, Suttle CM. Global prevalence of childhood cataract: a systematic review. Eye (Lond). 2016;30(9):1160–1169. doi:10.1038/eye.2016.156
   PubMed Web of Science ®Google Scholar
• Acosta R, Hoffmeister L, Roman R, Comas M, Castilla M, Castells X. [Systematic review of population based studies of the prevalence of cataracts]. Arch Soc Esp Oftalmol. 2006;81(9):509–516. Indonesian. doi:10.4321/s0365-66912006000900005.
   Google Scholar
• Zarbin MA, Casaroli-Marano RP, Rosenfeld PJ. Age-related macular degeneration: clinical findings, histopathology and imaging techniques. Dev Ophthalmol. 2014;53:1–32. doi:10.1159/000358536
   Google Scholar
• Dettoraki M, Kattamis A, Ladas I, et al. Electrophysiological assessment for early detection of retinal dysfunction in beta-thalassemia major patients. Graefes Arch Clin Exp Ophthalmol. 2017;255(7):1349–1358. doi:10.1007/s00417-017-3650-9
   Web of Science ®Google Scholar
• Wu P-C, Huang H-M, Yu H-J, Fang P-C, Chen C-T. Epidemiology of Myopia. Asia Pac J Ophthalmol (Phila). 2016;5(6):386–393. doi:10.1097/APO.0000000000000236
   PubMed Web of Science ®Google Scholar
• Nuzzi R, Schiavino R. Geriatric ophthalmology. Panminerva Med. 1993;35(1):36–46. PMID: 8316402.
   Web of Science ®Google Scholar
• Weale RA. Epidemiology of refractive errors and presbyopia. Surv Ophthalmol. 2003;48(5):515–543. doi:10.1016/S0039-6257(03)00086-9
   PubMed Web of Science ®Google Scholar